Work

[Evaluation of the efficacy and safety profile of tenofovir amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis].

Year: 2024

Type: other

Abstract: TMF has a relatively better efficacy and safety profile than TAF at 48 weeks in patients with hepatitis B virus-related cirrhosis.

Source: PubMed

DOI: 10.3760/cma.j.cn501113-20240904-00475

Authors: K Y Hao, X Jiang, Y Dong, H N Sun, Y C Yu

Institutions: Nanjing General Hospital of Nanjing Military Command, Nanjing University

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4407800766

Cites:

Cited by:

Related to: 10